Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer

BACKGROUND: More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance. Although the mechanisms of hormone therapy resistance remain unclear, aberrant DNA methylation has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao-ran, Zhang, Ru-yan, Gong, Hao, Rugo, Hope S., Chen, Ling-bo, Fu, Yuan, Che, Jian-wei, Tie, Jian, Shao, Bin, Wan, Feng-ling, Kong, Wei-yao, Song, Guo-hong, Jiang, Han-fang, Xu, Guo-bing, Li, Hui-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057408/
https://www.ncbi.nlm.nih.gov/pubmed/32129154
http://dx.doi.org/10.1177/1533033819896331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057408/
https://www.ncbi.nlm.nih.gov/pubmed/32129154
http://dx.doi.org/10.1177/1533033819896331

Ejemplares similares